면역세포를 이용한 항암세포 치료제 개발 전문기업입니다. 차별화된 기술개발로 보다 많은 환자에게 희망을 주는 기업으로 성장해 나가고 있습니다.
Investors 4
| Date | Name | Website |
| - | JX Partner... | jxpartners... |
| - | AJU IB Inv... | ajuib.co.k... |
| - | Company K ... | kpartners.... |
| - | Mirae Asse... | vc.miraeas... |
Mentions in press and media 1
| Date | Title | Description |
| 13.06.2022 | Curocell announced impressive CR rate in Phase 1 study with anbal-cel, the next generation CD19 CAR-T integrated OVIS™ platform | - 82% ORR (9 of 11 patients) and 82% (9 of 11 patients) CR rate documented after anbal-cel treatment to the patients in relapsed/refractory large B-cell lymphoma - 2 out of 3 patients dosed with 2x105 cells/kg of anbal-cel lasting the compl... |